<?xml version="1.0" encoding="UTF-8"?>
<p id="Par56">The inclusion criteria are as follow: 
 <list list-type="bullet">
  <list-item>
   <p id="Par57">Patients older than 18 years</p>
  </list-item>
  <list-item>
   <p id="Par58">Good general condition: WHO performance status ≤1</p>
  </list-item>
  <list-item>
   <p id="Par59">Patients with histological proof of breast, non-small cell lung, or prostate cancer</p>
  </list-item>
  <list-item>
   <p id="Par60">Absence of co-morbidity contra-indicating radio-chemotherapy or surgery</p>
  </list-item>
  <list-item>
   <p id="Par61">Primary tumor accessible to curative-intent treatment (surgery, chemoradiation…) for patients with synchronous metastases (ie randomization after treatment of primitive cancer)</p>
  </list-item>
  <list-item>
   <p id="Par62">Patients with between 1 and 3 synchronous or metachronous bone metastases as defined by NaF-PET or conventional SPECT-CT scan and spinal MRI (if necessary) within 6 weeks before randomization</p>
  </list-item>
  <list-item>
   <p id="Par63">Bones metastases treatable by SBRT</p>
  </list-item>
  <list-item>
   <p id="Par64">Primary cancer considered to be controlled or accessible to curative-intent treatment (surgery, chemoradiation…) in case of locoregional reccurence for metachronous bone oligo-metastatic disease</p>
  </list-item>
  <list-item>
   <p id="Par65">Women of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy;</p>
  </list-item>
  <list-item>
   <p id="Par66">Patients who have received the information sheet, dated and signed the informed consent form</p>
  </list-item>
  <list-item>
   <p id="Par67">Affiliated to the social security system</p>
  </list-item>
 </list>
</p>
